This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Dini, V. Articles by Barachini, P. Search for Related Content PubMed PubMed Citation Articles by Dini, V. Articles by Barachini, P. Social Bookmarking                         What's this?

Improvement of Idiopathic Pyoderma Gangrenosum During Treatment With Anti-Tumor Necrosis Factor Alfa Monoclonal Antibody

Wound Healing Research Unit, Department of Dermatology, University of Pisa, Pisa, Italy

Marco Romanelli, MD, PhD

Wound Healing Research Unit, Department of Dermatology, University of Pisa, Pisa, Italy, m.romanelli{at}med.unipi.it

MariaStefania Bertone, MD

Wound Healing Research Unit, Department of Dermatology, University of Pisa, Pisa, Italy

Sara Talarico, MD

Department of Rheumatology, University of Pisa, Pisa, Italy

Stefano Bombardieri, MD

Department of Rheumatology, University of Pisa, Pisa, Italy

Paolo Barachini, MD

Wound Healing Research Unit, Department of Dermatology, University of Pisa, Pisa, Italy

Pyoderma gangrenosum (PG) is an inflammatory ulcerative condition of unknown etiology. An autoimmune mechanism including immune complex—mediated neutrophilic vascular reactions has been suggested. The role of tumor necrosis factor (TNF) in PG remains unclear. Evidence supports the idea that TNF plays a role in chronic inflammation and migration of neutrophils to these lesions. PG is frequently associated with various diseases, but up to 50% of cases are idiopathic. There are several reports describing the successful use of infliximab^TM (Remicade ®, Centocor, Inc, Horsham, Pa), a chimeric antitumor necrosis factor monoclonal antibody, in the treatment of inflammatory bowel disease— associated PG, but there have been few reported cases of infliximab in the treatment of idiopathic PG. The authors present a dramatic improvement in 4 cases of idiopathic PG of the lower leg treated with infliximab.

Key Words: pyoderma gangrenosum • infliximab^TM • leg ulcers • anti-TNF alfa

The International Journal of Lower Extremity Wounds, Vol. 6, No. 2, 108-113 (2007)
DOI: 10.1177/1534734607300912


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?